Loading…
← CockpitCompetitor Analysis › 605016.SS Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Class AOpen in the cockpit ↗

Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Class A605016.SSCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Food: Specialty/Candy

Chinese maker of functional food ingredients such as dietary fiber, resistant dextrin and prebiotics for food/beverage makers.

≈ A Chinese food-ingredient specialist, akin to a smaller Tate & Lyle/IngredionMomentum leader 80
Mkt cap
$1.25B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$11.3M
20-day average traded
Fwd P/E
19.1×
forward earnings
ROIC−WACC
+11.1 pp
WACC 8.0%
Hurdle
-13 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥20.10
1D+1.4%
1W+2.2%
1M+4.8%
3M-0.2%
6M-26.2%
YTD-6.9%
1Y-1.4%
ATR %3.8%
52w lowhigh30.9% off high

What Shandong Bailong Chuangyuan Bio-Tech does

Chinese maker of functional food ingredients such as dietary fiber, resistant dextrin and prebiotics for food/beverage makers.

In one line: A Chinese food-ingredient specialist, akin to a smaller Tate & Lyle/Ingredion.

Products and services

  • Resistant dextrin/dietary fiber
  • Prebiotic syrups
  • Specialty sweeteners

Customers

  • Food & beverage manufacturers (domestic & export)

Where it sits in the supply chain

  • Specialty ingredients
  • Functional food ingredients
  • Dietary fiber, prebiotics, sweetener…

What could go right

  • Global demand for sugar-reduction/gut-health ingredients

What could go wrong

  • Customer concentration
  • Raw material cost swings

Moat: narrow (process know-how, customer qualification). Technical know-how in functional fiber production and qualified relationships with F&B makers.

Headquarters: Yucheng, Shandong, China · Employees: 990

Named competitors

Shandong Bailong Chuangyuan Bio-Tech at a glance

Size Shandong Bailong Chuangyuan Bio-Tech (605016.SS) is a China Consumer Staples company (Food: Specialty/Candy) with a market value of $1.25B, the 1777th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥20.10 on 18 Nov 2026.

Performance Over six months the shares fell 26.2%, against -12.6% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 19.1% over the last twelve months (peer median +7.1%); the operating margin is 31.6% (peer median 6.1%).

Valuation It trades at 19.1× forward earnings against a peer median of 23.8× (10th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.1 points above its cost of capital (8.0% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 87605016.SS 76
Six months, rebased to 100: Shandong Bailong Chuangyuan Bio-Tech against the median of its 20 peers (local-currency closes).

Shandong Bailong Chuangyuan Bio-Tech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.54BCN¥1.38BCN¥1.14BCN¥864MCN¥719M
Revenue growth—+21%+32%+20%—
Gross profitCN¥718MCN¥560MCN¥367MCN¥272MCN¥219M
EBITDAn/aCN¥536MCN¥339MCN¥241MCN¥194M
Net incomeCN¥397MCN¥369MCN¥246MCN¥193MCN¥151M
Free cash flowCN¥9.01M-CN¥157MCN¥28.8M-CN¥109M-CN¥13.5M
Capital expenditureCN¥598MCN¥297MCN¥282MCN¥312MCN¥176M
Total debtCN¥682MCN¥246MCN¥125MCN¥29.6MCN¥12.0M

Quarterly statements and history in the cockpit →

Shandong Bailong Chuangyuan Bio-Tech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-10%0%0028912602MANORAMA05460336BIKAJI0049902201SENEAITM603027600929FLO600866281500437028110018002001605016.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Bailong Chuangyuan Bio-Tech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%20×40×60×0028912602MANORAMA05460336BIKAJI0049902201SENEAITMCCL603027600929FLO6008662811605016.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Bailong Chuangyuan Bio-Tech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%MANORAMA0336BIKAJI2201SENEACCL6030270043702811001800605016.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Bailong Chuangyuan Bio-Tech is the large dot.

Shandong Bailong Chuangyuan Bio-Tech competitors and peer comparison

Head to head with its named competitors (605016.SS vs INGR vs TATE.L vs 000930.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shandong Bailong Chuangyuan Bio-Tech 605016.SS$1.25B-26%+19%32%19.1×9.1%
Ingredion INGR$5.60B-11%-1%11%9.3×-5.6%
Tate & Lyle TATE.L$3.27B+11%+2%8%15.8×13.2%
COFCO Biotechnology 000930.SZ$1.23B-18%-9%-2%n/an/a

How Shandong Bailong Chuangyuan Bio-Tech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Bailong Chuangyuan Bio-Tech against its 20 peers (data as of 18 Nov 2026)
Measure605016.SSPeer medianRank in peer set
1-month return+4.8%-0.2%3rd highest of 21
6-month return-26.2%-12.6%5th lowest of 21
Distance from 52-week high-30.9%-24.4%10th lowest of 21
Revenue growth (TTM)+19.1%+7.1%5th highest of 21
Operating margin31.6%6.1%highest of 21
Forward P/E19.1×23.8×10th cheapest of 20
Growth the price implies (Req g, 7 yrs)9.1%-1.6%5th most demanding of 13
Growth delivered (Del g)+22.5%+7.7%3rd highest of 13
Hurdle (Req g minus delivered)-13.4 pp-11.8 pp4th least demanding of 13
ROIC minus cost of capital+11.1 pp+0.3 pp2nd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shandong Bailong Chuangyuan Bio-Tech 605016.SSChina$1.25B-26%+19%32%19.1×9.1%+22.5%
Yantai China Pet Foods 002891.SZChina$1.25B-17%+21%4%29.4×n/an/a
Nisshin OilliO 2602.TJapan$1.25B+19%+9%4%18.6×n/an/a
Manorama Industries MANORAMA.NSIndia$1.26B+36%+60%24%36.1×32.6%+46.9%
Fufeng 0546.HKHong Kong$1.24B-36%+1%4%7.0×n/an/a
Huabao International 0336.HKHong Kong$1.27B-13%+13%3%23.8×14.6%-2.7%
Bikaji Foods International BIKAJI.NSIndia$1.28B-29%+13%9%42.4×39.9%+17.5%
Lotte 004990.KSSouth Korea$1.21B-23%0%1%70.0×n/an/a
Morinaga & 2201.TJapan$1.32B+1%+5%9%12.6×-5.6%+7.1%
Seneca Foods SENEAUnited States$1.18B+23%+12%8%11.8×-10.4%+2.5%
Italmobiliare ITM.MIItaly$1.17B-13%+8%14%14.0×n/an/a
CCL Products (India) CCL.NSIndia$1.36B-13%+24%13%25.4×17.8%+29.1%
Qianhe Condiment & Food 603027.SSChina$1.38B-18%-6%14%24.0×2.5%+8.8%
Snowsky Salt Industry 600929.SSChina$1.14B-31%+32%1%51.8×n/an/a
Flowers Foods FLOUnited States$1.11B-27%+1%6%8.2×-6.6%+3.7%
Star Lake Bioscience 600866.SSChina$1.07B-24%-3%0%37.4×n/an/a
ARIAKE JAPAN 2815.TJapan$1.06B-4%+5%17%17.6×-6.1%+6.1%
Nongshim 004370.KSSouth Korea$1.52B-10%+6%6%11.0×-17.9%+5.9%
Kagome 2811.TJapan$1.54B+11%+3%7%24.8×2.6%+10.0%
ORION 001800.KSSouth Korea$1.02B-7%+16%15%n/a-15.9%+8.3%
NIPPN 2001.TJapan$1.55B+10%+2%5%11.8×n/an/a

Questions

Who are Shandong Bailong Chuangyuan Bio-Tech's main competitors?
Named competitors: Ingredion (INGR), Tate & Lyle (TATE.L), COFCO Biotechnology (000930.SZ). The cockpit's measured peer set (industry) also includes Yantai China Pet Foods (002891.SZ), Nisshin OilliO (2602.T), Manorama Industries (MANORAMA.NS), Fufeng (0546.HK), Huabao International (0336.HK), Bikaji Foods International (BIKAJI.NS).
Is Shandong Bailong Chuangyuan Bio-Tech expensive compared with its peers?
On forward p/e it trades at 19.1× against a peer median of 23.8×, 10th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Shandong Bailong Chuangyuan Bio-Tech stock performed?
Over six months to 18 Nov 2026 the shares returned -26.2% against -12.6% for the median peer; over one year -1.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.